Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.